Navigation Links
KaloBios' KB001 Anti-Pseudomonas Antibody Study Published in Pediatric Pulmonology
Date:9/18/2013

.
  • KB001-A, an anti-PcrV mAb fragment, is partnered exclusively with Sanofi and is being developed for the prevention and treatment of Pa infection. KaloBios has retained rights for the CF indication and has initiated a 180 patient Phase 2 study in CF subjects with chronic Pa lung infection in the United States. KaloBios received Orphan Drug Status from the European Commission regarding its applications for KB001-A for the treatment of Pa lung infection in CF. Sanofi is pursuing a ventilator-associated pneumonia prevention indication in the intensive care setting, an indication which has received U.S. FDA Fast Track Designation.
  • KB004, an anti-EphA3 mAb, has potential in treating hematologic malignancies and solid tumors. KaloBios is currently testing this drug in a Phase 1 study in subjects with hematologic malignancies.
  • All of the company's antibodies were generated using its proprietary Humaneered® technology, a method that converts nonhuman antibodies (typically mouse) into recombinant antibodies that have a high binding affinity to their target and are designed for chronic therapeutic use. The company believes that antibodies produced using its Humaneered® technology offer important clinical and economic advantages over antibodies generated by other methods in terms of high binding affinity, high manufacturing yields, and minimal to no immunogenicity (inappropriate immune response) upon repeat administration in humans.

    For more information on KaloBios Pharmaceuticals, please visit our web site at http://www.kalobios.com.

    Forward Looking Statements

    This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's clinical development of KB001-
    '/>"/>

    SOURCE KaloBios Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
    2. KaloBios Pharmaceuticals Completes Initial Public Offering
    3. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
    4. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma
    5. Bioassociate Announces Initiation of Coverage on KaloBios Pharmaceuticals, Inc.
    6. KaloBios to Present at Future Leaders in the Biotech Industry Conference
    7. KaloBios Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
    8. KaloBios to Present at Needham Healthcare Conference
    9. KaloBios Reports First Quarter 2013 Financial Results
    10. KaloBios to Present at Stifel Healthcare Conference 2013
    11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
    (Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
    (Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
    Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
    ... N.C., Feb. 10, 2012  Viztek, the digital radiology solution ... U-Arm at Edison Metuchen Orthopaedic Group (EMOG) in Edison, ... psychiatrist with onsite x-ray and access to an MRI facility ... EMOG performs between 65 and 85 x-ray procedures ...
    ... PRINCETON, N.J., Feb. 10, 2012 Soligenix, Inc. ... stage biopharmaceutical company, announced preliminary results today from ... time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), ... The Phase 1/2 protocol BDP-ENT-01 was ...
    Cached Medicine Technology:Soligenix Announces Results From Its Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis 2Soligenix Announces Results From Its Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis 3Soligenix Announces Results From Its Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis 4Soligenix Announces Results From Its Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis 5
    (Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
    (Date:4/17/2014)... In a review published in the April issue ... of The Feinstein Institute for Medical Research, says it,s ... community,s approach to treating sepsis, which kills ... , Sepsis occurs when molecules released into the bloodstream ... the body. Inflammation is necessary for maintaining good health ...
    (Date:4/17/2014)... Northwestern University synthetic biology team has created a ... programmable therapeutics that could travel the body and ... , Engineering cell-based, biological devices that monitor and ... clinical synthetic biology. However, no existing technology enabled ... patient,s physiological state and respond in a customized ...
    (Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
    (Date:4/17/2014)... YORK, NY (April 16, 2014) The cause of ... a new study proposes that neurons may be mistaken ... immune system, similar to the way autoimmune diseases like ... the body,s cells. The study was published April 16, ... a new, and likely controversial, idea in Parkinson,s disease; ...
    Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2
    ... Mechanics has recognized three NSF-funded projects with innovation ... who have lost it; a system that uses "controlled ... and an inexpensive medical microscope built for cell-phones that ... cells. Those projects, along with 16 others, are ...
    ... system faces a challenge in overcoming communication barriers ... the University of Gothenburg, Sweden. The thesis ... refugees have found it hard to gain access ... are entitled to. Interpreters were sometimes assigned on ...
    ... News) -- The brains of new mothers actually get ... The researchers, most from the Yale University School of ... in levels of certain hormones just after birth. They reported ... and motivation. The researchers also found that mothers who ...
    ... with a type of metastatic liver cancer --hepatocellular carcinoma ... according to Penn State College of Medicine researchers. Hepatocellular ... deaths in the world. Hanning You, M.D., Ph.D., postdoctoral ... pediatrics and pharmacology, targeted c-Met, a known receptor for ...
    ... dangers of the traditional negative physical risk factors ... overweight. But far less research has focused on ... psychological and social supports. New research by Margie ... the Brandeis Psychology Department explores the psychological roots ...
    ... team of physicians and scientists from the Cedars-Sinai Regenerative Medicine ... PhD has been awarded a three-year $1.9 million grant from ... clinical trials for what could become the first biological treatment ... patients. The grant was announced ...
    Cached Medicine News:Health News:Popular Mechanics breakthrough awardees announced 2Health News:Communicating through interpreters -- a challenge for health care 2Health News:New Moms' Brains May Grow After Childbirth 2Health News:Personalized treatment may help some liver cancer patients 2Health News:Positive social traits trump bad health habits 2Health News:Cedars-Sinai awarded $1.9 million from CIRM to develop stem cell treatments for osteoporosis 2
    ... with BD Xstar Blade includes a specially ... blade in prodedure and handling. The ... grind-less process for manufacturing surgical blades. ... consistency. The arch style, single-bevel geometry ...
    ... Knife with BD Xstar Blade includes a ... the blade in prodedure and handling. ... a grind-less process for manufacturing surgical blades. ... and consistency. The arch style, single-bevel ...
    Bio-Rad's Genetic Systems HIV-1/HIV-2 PLUS O EIA is a unique assay that detects the broadest range of HIV....
    An advanced microprocessor-controlled unit with superior reliability and reproducible power. Its modern electronics provides the precision and control a surgeon expects....
    Medicine Products: